1195768-22-9

Basic information

• Product Name: N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(1-methylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide
• Synonyms: N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(1-methylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide
• CAS NO: 1195768-22-9
• Molecular Weight: 524.975
• Mol File: 1195768-22-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(1-methylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(1-methylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide(1195768-22-9)
• EPA Substance Registry System: N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(1-methylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide(1195768-22-9)

Safety Data

• Hazardous Substances Data: 1195768-22-9(Hazardous Substances Data)

Upstream product

• 946126-94-9 2-fluoro-3-nitrobenzoic acid methyl ester 
• 437-86-5 2-fluoro-3-nitrotoluene 
• 317-46-4 2-fluoro-3-nitro-benzoic acid 
• 161957-56-8 3-bromo-2-fluorobenzoic acid 
• 206551-41-9 2-fluoro-3-bromobenzoic acid methyl ester 
• 1042055-86-6 methyl 3-((tert-butoxycarbonyl)amino)-2-fluorobenzoate 
• 1195768-20-7 N-(3-(2-(2-chloropyrimidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide 
• 1195768-19-4 3-(2,6-difluorobenzenesulfonamido)-2-fluorobenzoic acid methyl ester 
• 1195768-18-3 3-amino-2-fluorobenzoic acid methyl ester 
• 914223-43-1 3-amino-2-fluoro benzoic acid 
• 13515-65-6 thioisobutyramide 

Downstream Products

• 1195764-77-2 2,6-Difluoro-N-{2-fluoro-3-[2-(1-methylethyl)-5-(2-{[2-(methylsulfonyl)ethyl]amino}-4-pyrimidinyl)-1,3-thiazol-4-yl]phenyl}benzenesulfonamide 
• 1244644-50-5 C₃₁H₂₈F₃N₇O₃S₂ 

Relevant articles and documents

Discovery of dabrafenib: A selective inhibitor of Raf Kinases with antitumor activity against B-Raf-driven tumors

Hyperactive signaling of the MAP kinase pathway resulting from the constitutively active B-RafV600E mutated enzyme has been observed in a number of human tumors, including melanomas. Herein we report the discovery and biological evaluation of GSK2118436, a selective inhibitor of Raf kinases with potent in vitro activity in oncogenic B-Raf-driven melanoma and colorectal carcinoma cells and robust in vivo antitumor and pharmacodynamic activity in mouse models of B-RafV600E human melanoma. GSK2118436 was identified as a development candidate, and early clinical results have shown significant activity in patients with B-Raf mutant melanoma.

THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS

The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents